LAVIPHARM S.A. NA EO 1 (BXA0) — Working Capital to Net Assets Ratio
LAVIPHARM S.A. NA EO 1 (BXA0) has a Working Capital to Net Assets ratio of 11.1% as of December 2024. Working capital of €5.88 Million (current assets of €45.00 Million minus current liabilities of €39.12 Million) is measured against net assets of €52.97 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See operational self-sufficiency of LAVIPHARM S.A. NA EO 1 to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
LAVIPHARM S.A. NA EO 1 Working Capital to Net Assets (2021–2024)
This chart shows how LAVIPHARM S.A. NA EO 1's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 11.1%, reflecting working capital of €5.88 Million against net assets of €52.97 Million EUR. For the complete balance sheet picture, see balance sheet size of LAVIPHARM S.A. NA EO 1.
Annual Working Capital to Net Assets for LAVIPHARM S.A. NA EO 1 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for LAVIPHARM S.A. NA EO 1 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check BXA0 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 11.1% | €5.88 Million | €52.97 Million | €45.00 Million | €39.12 Million | ▼ -11.9 pp |
| 2023 | 23.0% | €9.85 Million | €42.77 Million | €45.65 Million | €35.80 Million | ▲ +23.4 pp |
| 2022 | -0.3% | €-140.00K | €40.31 Million | €45.60 Million | €45.74 Million | ▼ -152.4 pp |
| 2021 | 152.0% | €-15.11 Million | €-9.94 Million | €25.96 Million | €41.07 Million | — |